Market capitalization | $130.84m |
Enterprise Value | $95.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.74 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-57.43m |
Free Cash Flow (TTM) Free Cash Flow | $-58.58m |
Cash position | $120.35m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Instil Bio Inc forecast:
3 Analysts have issued a Instil Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.93 -3.93 |
15%
15%
|
|
EBITDA | -54 -54 |
48%
48%
|
EBIT (Operating Income) EBIT | -57 -57 |
47%
47%
|
Net Profit | -75 -75 |
62%
62%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
Head office | United States |
CEO | Bronson Crouch |
Employees | 49 |
Founded | 2018 |
Website | www.instilbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.